Glaukos’ (GKOS) Sell (D-) Rating Reaffirmed at Weiss Ratings

Glaukos (NYSE:GKOS)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

A number of other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group initiated coverage on shares of Glaukos in a report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 target price for the company. UBS Group boosted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. BTIG Research reissued a “buy” rating and set a $118.00 target price on shares of Glaukos in a research report on Wednesday, September 10th. Zacks Research cut shares of Glaukos from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 15th. Finally, Truist Financial reduced their target price on shares of Glaukos from $126.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $118.00.

Glaukos Stock Performance

NYSE:GKOS opened at $87.55 on Wednesday. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $88.01 and a two-hundred day moving average price of $93.07. Glaukos has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a market capitalization of $5.02 billion, a P/E ratio of -53.06 and a beta of 0.76.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The company’s quarterly revenue was up 29.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.52) earnings per share. Glaukos has set its FY 2025 guidance at EPS. As a group, research analysts expect that Glaukos will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Glaukos

Hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its stake in shares of Glaukos by 1,206.6% in the third quarter. Assenagon Asset Management S.A. now owns 157,545 shares of the medical instruments supplier’s stock worth $12,848,000 after acquiring an additional 145,487 shares during the last quarter. Corient Private Wealth LLC boosted its stake in Glaukos by 5.7% during the second quarter. Corient Private Wealth LLC now owns 31,599 shares of the medical instruments supplier’s stock worth $3,264,000 after buying an additional 1,702 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Glaukos by 3.7% during the second quarter. Thrivent Financial for Lutherans now owns 42,017 shares of the medical instruments supplier’s stock worth $4,340,000 after buying an additional 1,518 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in Glaukos by 11.4% during the second quarter. Public Sector Pension Investment Board now owns 194,842 shares of the medical instruments supplier’s stock worth $20,125,000 after buying an additional 20,006 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co boosted its stake in shares of Glaukos by 1.7% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 60,834 shares of the medical instruments supplier’s stock valued at $6,290,000 after purchasing an additional 1,000 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.